Abstract 2866
Background
In the Netherlands, hospice care is provided in professional-driven hospices and volunteer-driven hospices. To date, insight is lacking whether the care provided in hospices is appropriate to meet the patient’s needs and wishes. The aim is to gain insight into the characteristics of patients admitted in hospices, their needs and wishes and the care they receive.
Methods
A retrospective patient record study of 1200 hospice patients in the Netherlands. Preliminary results are shown for the first 203 patients. Inclusion criteria are deceased, adult patients admitted in hospice in 2017-2018.The following outcomes were included: Patient characteristics: demographics, disease characteristics, multidimensional symptoms, needs and wishes. Care characteristics: measurement instruments and multidimensional care. Descriptive statistisc was used for analyses.
Results
Preliminary results of 203 patients (mean age 74.8 years, 51.8% woman, 84% cancer diagnoses) from 13 hospices show that initiative for admission is mostly taken by the patient or their family (65.7%). Reasons for admission were described as physical symptoms (73.1%), preferred location of dying (16.1%) and social problems (9.7%). Patients were mostly admitted for last-resort (96.4%) and most patients were in the phase of symptom palliation (79.4%). Problems that were most described were delirium (18.6%), decubitus (12.4%) and edema (6.2%). On average, 10.6 interventions were performed in the first 72 hours per patient. Most were within the physical dimension (76.6%) and least in the social dimension (2.3%). Of the 11 different measurement tools identified, a symptom diary (20.7%) and a palliative assessment (17.2%) were most frequent used.
Conclusions
A preliminary overview of hospice patients and the care they receive was presented. The study is work in progress. Additional data and a comparison between organizational structures of hospices will be presented during the congress.
Clinical trial identification
Editorial acknowledgement
R. Koorn, F. van der Baan, E. de Graaf, S. Teunissen.
Legal entity responsible for the study
S.C.C.M. Teunissen.
Funding
ZonMw.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
3489 - Overall Survival (OS) and Metastasis-Free Survival (MFS) in men with Biochemically Relapsed (BCR) Prostate Cancer after radical prostatectomy (RP) managed with deferred Androgen Deprivation Treatment (ADT): A combined Johns Hopkins and CPDR study
Presenter: Catherine Marshall
Session: Poster Display session 3
Resources:
Abstract
4606 - ARCHES – the role of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): Post hoc analyses of high and low disease volume and risk groups
Presenter: Arnulf Stenzl
Session: Poster Display session 3
Resources:
Abstract
2975 - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study).
Presenter: Orazio Caffo
Session: Poster Display session 3
Resources:
Abstract
2708 - Real-world analysis of patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving vs not receiving chemotherapy in the treatment sequence
Presenter: Alicia Morgans
Session: Poster Display session 3
Resources:
Abstract
2134 - Baseline fracture risk in men with prostate cancer starting the STAMPEDE trial
Presenter: Janet Brown
Session: Poster Display session 3
Resources:
Abstract
3504 - Risk of falls and fractures in patients with castration resistant prostate cancer (CRPC) treated with new hormonal agents – a meta-analysis of randomized controlled trials.
Presenter: Rodrigo Coutinho Mariano
Session: Poster Display session 3
Resources:
Abstract
2342 - Pain progression at initiation of chemotherapy in metastatic Castration-Resistant Prostate Cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of FIRSTANA
Presenter: Nicolas Delanoy
Session: Poster Display session 3
Resources:
Abstract
5331 - Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
Presenter: Holger Palmedo
Session: Poster Display session 3
Resources:
Abstract
2823 - Time to castration resistant prostate cancer (CRPC) and the risk of developing immune disorders
Presenter: Vincenza Conteduca
Session: Poster Display session 3
Resources:
Abstract
1500 - Retrospective evaluation of neutropenic admission events in metastatic or high-risk hormone-sensitive prostate cancer (HSPC) patients having docetaxel chemotherapy upfront or for castrate-resistant prostate cancer (CRPC) in STAMPEDE
Presenter: Harriet Mintz
Session: Poster Display session 3
Resources:
Abstract